The motivation for the work stems from a grim statistical reality. Roughly 1.4 million Americans live in nursing homes, and within the first year of the pandemic, most facilities in the United States experienced outbreaks, with residents accounting for an estimated 30 to 50 percent of COVID-19 deaths. Previous modeling studies have largely concentrated on resident-focused measures such as isolation, personal protective equipment, testing, and visitor restrictions. Far fewer have asked how the structure of the workforce itself—staff shortages, low wages, multiple job holding, and weak benefits—shapes the epidemiology of infection inside these buildings.

That gap matters because the economics of nursing home work create well-documented transmission risks. Low compensation pushes many direct-care workers to hold jobs at two or even three facilities simultaneously, moving between buildings each week and potentially carrying the virus with them. The absence of paid time off means that a symptomatic worker who cannot afford unpaid leave may clock in anyway. And despite strong evidence that vaccination protects both staff and residents, skilled nursing facilities report some of the lowest vaccination rates among healthcare settings, reflecting persistent hesitancy and the lack of comprehensive institutional policies.

To capture these dynamics, the team, led by Abigail Sweet of North Carolina State University’s Biomathematics Graduate Program, constructed an agent-based model in which every individual—resident, healthcare personnel, or community member—is represented as a discrete agent moving through infection and hospitalization states. The synthetic populations were derived from 2010 U.S. Census data using the Framework for Reconstructing Epidemiological Dynamics, or FRED, which supplies demographic and spatial detail representative of the actual two million people living across Franklin, Jefferson, St. Charles, and St. Louis counties and the City of St. Louis. Zip-code-level data on social determinants of health were layered on to modulate mortality and hospitalization risk, while facility-specific characteristics such as bed capacity came from Centers for Medicare and Medicaid Services records and the LTCFocus dataset.

The technical architecture of the model is considerable. Ten submodels, each executed once per simulated day for 365 days, govern death, personnel replacement, infection transmission, hospital admission and discharge, recovery, retirement, nursing home admission and discharge, and vaccination. Transmission within facilities follows a stochastic formulation in which the infection probability per contact is combined with the prevalence of infection among residents, personnel, and the surrounding community, along with the number of daily contacts of each type. Because the model does not trace individual contacts, the probability that a given contact is infectious is approximated from the proportion of each category that is infected, recalculated at every time step for every facility. Infection status is then adjusted for each agent’s immunity, whether from prior infection or vaccination. Roughly 46 percent of simulated infections are asymptomatic, and transmission is only modeled after incubation periods of 5.47 days for asymptomatic and 2.63 days for symptomatic cases, reflecting the reduced per-contact transmission probability outside symptomatic illness.

Hospitals were included deliberately, because the movement of patients between acute care and skilled nursing facilities is a critical pathway. Up to 94 percent of nursing home residents arrive directly from hospital discharge, and many are rehospitalized as their complex medical needs evolve. Capturing these flows allowed the model to reproduce healthcare-associated exposure routes that would be invisible if facilities were simulated in isolation. The model was calibrated against empirical data collected by CMS through May 2023, focusing on discharge rates, average length of stay, and reported facility-level COVID-19 cases, and validated with 10-fold cross-validation. The experimental model achieved a root mean squared error of 0.063 against a naive baseline of 0.114 and explained approximately 70 percent of the variation in observed infection rates across facilities.

Each intervention scenario was simulated 250 times, and the results were striking in their pattern. In the baseline scenario, with no policies enforced, facilities recorded an average of 172.65 resident infections per year. The single most effective measure for protecting residents was compulsory paid sick leave, which removes symptomatic staff from the workforce pool. Combining sick leave with a full-time employment policy—which restricts each worker to a single facility at 40 hours per week instead of two or three jobs—cut resident infections by 12 percent, to 150.72, and slashed personnel infections by 45 percent, from 8.45 to 4.73 per facility. Full-time employment alone had the greatest impact on personnel infections, producing a reduction of nearly 35 percent, and on personnel-introduced outbreaks, which fell by more than half.

The vaccination mandate produced a more nuanced and somewhat sobering picture. Implementing the policy raised simulated personnel vaccination coverage from 48 percent to 81 percent, exceeding the roughly 80 percent threshold that earlier studies identified as necessary for meaningful effect. Yet the impact on resident infections remained minimal. The authors attribute this to two converging factors: the reduced efficacy of vaccines against later SARS-CoV-2 variants, and the sheer thinness of nursing home staffing, which meant that an 81 percent uptake translated to an average of only five additional vaccinated personnel per site. Larger facilities with more staff might see greater benefit, but the finding underscores that vaccination mandates alone, however well-intentioned, cannot substitute for broader workforce investment.

The outbreak findings add another dimension. Total outbreaks per facility, defined as any occurrence of two or more resident infections, changed by less than 2 percent across scenarios, but personnel-introduced outbreaks responded dramatically to staffing policies. Full-time employment alone reduced them by 51.73 percent, and combining it with sick leave or vaccination pushed the reduction to nearly 65 percent. This distinction matters because personnel-introduced outbreaks are precisely the events that facility administrators and public health agencies can most directly prevent through workforce policy, whereas outbreaks seeded by visitors fall largely outside institutional control, particularly now that federal visitor restrictions have long been lifted.

The study’s limitations are acknowledged candidly by its authors. The model assumes a simplified staffing structure without floating personnel or shift variability, excludes resident-to-personnel transmission to keep the computation tractable, omits privately funded facilities, and implements social determinants of health at a surface level that does not capture their co-occurrence. Even so, the central conclusion carries real policy weight: while no workforce intervention matched the protective power of isolation of symptomatic individuals, the combination of paid sick leave and full-time employment delivered meaningful reductions in infections among both residents and staff. Given the chronic nursing shortage, low wages, and burnout that continue to erode the long-term care workforce, the findings suggest that improving compensation and benefits is not merely a labor issue but an infection-control strategy—one that could make nursing homes safer for their residents while simultaneously making them more sustainable places to work. The modeling framework itself, publicly available on GitHub, is designed to extend beyond COVID-19 to other healthcare-associated infections in acute and post-acute settings.

Subject of Research: Agent-based modeling of workforce compensation and benefit policies on COVID-19 transmission in skilled nursing facilities

Article Title: Modeling the impact of healthcare personnel compensation and benefits on the spread of COVID-19 in skilled nursing facilities

Article References: Sweet, A., Rhea, S., Lenhart, S. M., Odoi, A., Lanzas, C., & Lloyd, A. (2026). Modeling the impact of healthcare personnel compensation and benefits on the spread of COVID-19 in skilled nursing facilities. PLOS Aging and Health, 1(3), e0000040. https://doi.org/10.1371/journal.page.0000040

Image Credits: AI Generated

DOI: 10.1371/journal.page.0000040

Keywords: COVID-19, skilled nursing facilities, agent-based model, healthcare personnel, paid sick leave, full-time employment, vaccination policy, nursing shortage, infection control, long-term care, outbreak modeling, workforce policy

The study, published in eClinicalMedicine, drew on the SCIFI-PEARL project, a population-based research infrastructure that links multiple Swedish national and regional registers through the country’s unique personal identification number. The team, led by Lisa Morris and colleagues at the University of Gothenburg and collaborating institutions, focused on adults living in Stockholm and Västra Götaland, the two largest regions in Sweden, which together account for nearly 40 percent of the national population. Because post COVID-19 condition is largely managed in primary care, access to primary healthcare databases was a decisive advantage, allowing the researchers to capture diagnoses that would be missed in studies restricted to hospital records.

The methodological design was a sequential propensity score-matched cohort study, an approach well suited to observational vaccine research. Rather than comparing vaccinated with unvaccinated people, a comparison now nearly impossible in highly immunised populations, the investigators compared individuals who received a fourth dose with closely matched counterparts who had received three doses but had not yet received a fourth at the same calendar time. Propensity scores were estimated using a Cox proportional hazards model that incorporated a remarkably rich set of covariates: age, gender, education, occupation, income, marital status, urbanicity, country of birth, parents’ country of birth, nursing home residence, home care services, prior healthcare contacts, pregnancy, a wide range of comorbidities, medication use, and previous COVID-19 infection classified as non-hospitalised or hospitalised. Matching was performed within strata defined by gender, age group, the week of the third dose, and the presence or absence of risk factors for severe acute COVID-19.

This procedure produced two groups of 801,869 individuals each, drawn from a total of roughly 1.4 million unique people. Balance between the groups was excellent, with all standardised mean differences below the conventional threshold of 0.1, meaning the three-dose and four-dose groups were statistically indistinguishable across the measured characteristics. Each participant was followed from the index date, the day the matched exposed individual received the fourth dose, until a post COVID-19 condition diagnosis, a new vaccination, migration, death, six months of follow-up, or the end of the study in February 2024. When one member of a matched pair was censored because of new vaccination, the entire pair was censored to prevent informative censoring from skewing the comparison.

The outcome was defined as a registered diagnosis of post COVID-19 condition using the ICD-10 code U09.9, recorded in either primary or specialist care. Sweden implemented this diagnosis code clinically in October 2020, and the National Board of Health and Welfare recommends that physicians use it when a condition is judged to be associated with a previous COVID-19 infection. During follow-up, 388 individuals in the three-dose group and 268 in the four-dose group received such a diagnosis. The incidence rate was 1.67 per 1000 person-years among those with three doses and 1.14 per 1000 person-years among those with four doses, an absolute difference of just over half a case per 1000 person-years.

In the Cox regression analysis, the hazard ratio for post COVID-19 condition after a fourth dose was 0.69, corresponding to a vaccine effectiveness of 31 percent. The researchers then asked whether this protection differed between people with and without risk factors for severe acute COVID-19, a group defined by the Swedish Public Health Agency as including people aged 65 or older, nursing home residents, those receiving home care, pregnant women, and people with conditions such as diabetes, cardiovascular disease, chronic respiratory disease, obesity, renal failure, liver disease, Down’s syndrome, neuromuscular disease, or immunodeficiency. A statistically significant interaction confirmed that the effect did indeed differ. Among individuals with risk factors, vaccine effectiveness reached 38 percent, with an incidence rate difference of minus 0.82 per 1000 person-years. Among those without risk factors, effectiveness was a more modest 18 percent, and the absolute difference of minus 0.21 per 1000 person-years did not reach statistical significance.

The authors subjected their findings to an unusually thorough battery of sensitivity analyses. Repeating the matching with replacement, which allowed 99 percent of the exposed population to be included, produced essentially identical results. Alternative approaches to handling informative censoring, including inverse probability censoring weights and removing censoring for new vaccination altogether, yielded slightly lower estimates but preserved the overall pattern. Broadening the outcome to include the post-viral fatigue code G93.3 increased sensitivity and produced larger incidence rate differences, while excluding individuals diagnosed with other severe acute respiratory infections, a step designed to sharpen the specificity of the outcome, left the results unchanged. Restricting the analysis to index dates from April 2022 onwards, when the Omicron variant dominated, also gave findings consistent with the main analysis, suggesting the protection observed applies to the variant landscape that prevails today.

The study arrives at a moment when vaccination policy is being recalibrated across the world. A recent systematic review and meta-analysis had suggested that third or fourth doses reduce the odds of long COVID compared with a primary series alone, but the certainty of that pooled evidence was rated very low, and the underlying studies relied on self-reported vaccination status and symptoms. The Swedish register data, by contrast, capture every administered vaccine dose through a legally mandated national vaccination register, making exposure misclassification negligible. Earlier work by the same team had already shown that vaccination before a first SARS-CoV-2 infection reduces the risk of post COVID-19 condition in a dose-response fashion, but whether boosters still helped once most of the population carried pre-existing immunity remained genuinely uncertain. The new findings close that gap, showing that a fourth dose retains measurable, if modest, protective value even in this setting.

Interpretation of the mechanism requires care. Because infection is a prerequisite for post COVID-19 condition, and severe acute disease is a well-established risk factor for lingering symptoms, part of the observed protection likely reflects the vaccines’ continued ability to reduce infection and severe illness rather than a unique effect on the post-acute syndrome itself. Waning protection from the third dose may also have contributed to the excess of cases in the comparison group. The authors acknowledge other limitations: the U09.9 diagnosis code has not been formally validated, the registers cannot distinguish mild from severe long COVID, and only people who sought care and received a diagnosis are captured, probably missing milder cases. As an observational study, residual confounding and healthy vaccinee bias cannot be entirely excluded, although the design, in which most three-dose individuals eventually received a fourth dose, mitigates some of these concerns.

For policymakers, the practical message is nuanced. The absolute risk reduction of roughly half a case per 1000 person-years is small in the general population, and the benefit concentrates among those at higher risk of severe acute disease, precisely the group for whom the Swedish Public Health Agency’s 2025 health economic analysis judged continued vaccination most reasonable. With SARS-CoV-2 still circulating and reinfections carrying documented risks of hospitalisation and organ-specific sequelae, the study suggests that booster decisions should weigh not only protection against acute illness but also the emerging, quantifiable protection against long COVID, particularly for older and medically vulnerable individuals. The researchers call for further studies in other settings and with different measures of post COVID-19 condition to confirm and extend their findings.

Subject of Research: Effectiveness of a fourth COVID-19 vaccine dose against post COVID-19 condition in individuals with pre-existing immunity

Article Title: Booster dose of COVID-19 vaccine and its effectiveness against post COVID-19 condition in individuals with pre-existing immunity: a sequential propensity score-matched cohort study

Article References: Morris, L., Bülow, E., Li, H., Xu, Y., Gisslén, M., Nyberg, F., & Bygdell, M. (2026). Booster dose of COVID-19 vaccine and its effectiveness against post COVID-19 condition in individuals with pre-existing immunity: a sequential propensity score-matched cohort study. eClinicalMedicine, 100, Article 104215. https://doi.org/10.1016/j.eclinm.2026.104215

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104215

Keywords: COVID-19, long COVID, post COVID-19 condition, booster dose, vaccine effectiveness, SARS-CoV-2, Sweden, cohort study, propensity score matching, epidemiology, vaccination policy, public health

The study’s foundation is a simple but powerful epidemiological logic. If SARS-CoV-2 were still exerting a serious toll on the population, the age groups most vulnerable to the virus, principally those aged 60 and older, should show mortality rates above their pre-pandemic baselines. The researchers therefore calculated mortality rate ratios for every combination of sex and ten-year age band, dividing the 2024 death rate by the average rate across 2017 to 2019. A ratio above 1.00 would signal excess mortality; a ratio below 1.00 would suggest that deaths have fallen relative to before the pandemic. Confidence intervals were derived using the delta method on the log scale, allowing the team to distinguish signal from statistical noise.

The results were unambiguous for older Austrians. Despite 1,212 officially reported COVID-19 deaths in 2024, all-cause mortality rates in every stratum aged 40 and over were equal to or lower than before the pandemic, and in the 60-plus groups, the very populations at risk from the virus, rates were equal or lower in 2024 compared with 2019. In many of these strata the ratios fell well below 1.00. The team stress-tested this finding against several counterfactuals. An optimistic sensitivity analysis assumed that mortality would have continued improving after 2019 at the pace seen between 2012 and 2014, yielding an expected ratio of 0.929; five of the twelve age-sex strata aged 40 and over beat even that demanding benchmark. A trend-of-trends model trained on Austrian data from 2003 to 2019 produced an expected ratio of 0.976, and ten of twelve strata performed better than that. A Lee-Carter mortality forecasting model, fitted to age- and sex-specific rates from 2003 to 2019 and projected to 2024 via ARIMA with bootstrapped confidence intervals, showed observed 2024 life expectancy to be numerically higher than predicted in every age-sex stratum, significantly so for females across all age groups.

The picture for young Austrians was markedly different, and more troubling. Mortality rate ratios were elevated in the 10-to-19, 20-to-29 and 30-to-39 age bands, significantly so among men aged 30 to 39. Crucially, these increases cannot be attributed to COVID-19 itself: only a single individual across these young strata was recorded as having died of the disease in 2024. When the researchers decomposed the excess by cause, they found moderate increases spread across multiple high-level categories, with consistent rises in mental and behavioural disorders, external causes and diseases of the nervous system, though only external causes in the 10-to-19 group reached statistical significance. The authors suggest these patterns may reflect adverse consequences of the pandemic and the pandemic response, noting that escalating violence, alcohol problems, drug overdoses and suicides among young people have been documented in several countries and may constitute a lasting legacy that requires tracking and intervention.

The second half of the study tackles a subtler problem: how to count a COVID-19 death. Death certificates record an underlying cause of death, the condition that initiates the chain leading to death, along with other contributing conditions. In practice, anyone who dies with a positive SARS-CoV-2 test may be coded as a COVID-19 death even when other conditions are more relevant, a distinction that matters enormously in elderly and chronically ill populations. To address this, the team applied a weighted multiple-cause methodology to the full text of Austrian death certificates. In their main analysis, the underlying cause received a weight of 50 percent and all other mentioned causes shared the remaining 50 percent; when no other cause was listed, the underlying cause carried full weight. Ill-defined and duplicate causes were excluded. From more than 538,000 death certificates spanning 2019 to 2024, containing over 2.5 million non-duplicate ICD code mentions, the researchers constructed age-standardised rates for both unweighted underlying-cause counts and weighted counts.

The comparison between the two measures is the study’s most technically revealing result. If a cause is genuinely driving deaths, it should appear disproportionately as the underlying cause, and its weighted rate should approach its unweighted rate. For COVID-19 in the 60-plus age groups, the ratio of weighted to unweighted rates sat between 0.51 and 0.58, both in 2020 and in 2024, meaning the virus was far more likely to be listed as the underlying cause than other conditions were, and that this preference barely changed even as absolute death counts collapsed. Sensitivity analyses using alternative weighting schemes, equal weighting of all causes or double weight for the underlying cause, produced even lower weighted estimates, for example 4.15 versus a main-analysis 7.12 for 2024, and more stringent data-cleaning criteria left the COVID-19 findings intact. Taken together, the authors argue, these patterns point to systematic overcounting of COVID-19 deaths, potentially throughout the entire pandemic rather than only in its aftermath.

Supporting evidence comes from how COVID-19 behaved within the broader cause-of-death landscape. Respiratory diseases traditionally show a weighted-to-unweighted ratio well above 1.00, around 1.47 in 2019, because they are typically recorded as contributing rather than underlying conditions. During the pandemic years 2020 to 2023, once COVID-19 was stripped out of the respiratory category, other respiratory diseases fell markedly, and the category’s ratio rose to 1.64, as if COVID-19 had absorbed deaths that would otherwise have been attributed to pneumonia and related conditions. The causes most frequently co-mentioned with COVID-19 in 2024 were pneumonia, residual infections, hypertensive disease, ischaemic heart disease and renal failure, and even in 2024 COVID-19 was still listed as the underlying cause in 68 to 85 percent of those co-occurrences, down from 88 to 98 percent in 2020. Meanwhile, the apparent decline in ischaemic heart disease between 2019 and 2024 was, in the authors’ view, too large to reflect genuine improvement and may partly represent recoding of deaths with multiple comorbidities.

The Austrian findings align with a growing international literature based on clinical record audits. In Greece, only 64.9 percent of hospital deaths listed as COVID-19 were judged attributable or related to the virus upon audit. In Sweden, auditors found that 24 percent of certificate-listed COVID-19 deaths had absolutely no relationship to the infection, and that in most of the remainder COVID-19 was contributing rather than underlying; death certificates counted 799 underlying-cause COVID-19 deaths where clinical audit supported only 213. In Ireland, clinicians considered COVID-19 the primary cause in only 72.7 percent of audited deaths during the winter of 2021 to 2022, and Danish surveillance documented increasing overcounting with the Omicron variants. Notably, the feared undercounting in lower-income settings appears smaller than assumed: a Colombian audit found only 6 percent undercounting in 2021, although an Iranian audit of 339 certificates found major errors in 58 percent. The overall pattern suggests overcounting, not undercounting, has been the dominant error in well-resourced countries.

The study has limitations the authors acknowledge candidly. Without comorbidity data, the results cannot be generalised to specific high-risk populations such as immunocompromised patients or nursing home residents, among whom COVID-19 mortality may remain meaningful. Death certificate reporting itself is imperfect, with empirical studies suggesting major errors exceed 50 percent even in pre-pandemic years, and Austria’s automated IRIS coding algorithms may have favoured selecting COVID-19 as the underlying cause. There is also genuine uncertainty about the right counterfactual: whether mortality should have continued declining after 2019 at all, given that life expectancy gains in Austria and other high-income countries had already slowed dramatically in the decade before the pandemic, adding just 0.41 years between 2014 and 2019 compared with more than a year in each of the three preceding five-year periods. Some of the lower mortality among the very old in 2024 may reflect mortality displacement, the premature deaths during the pandemic of people who would otherwise have died a few years later.

Even so, the implications for policy are concrete. Accurate post-pandemic burden estimates directly shape vaccination recommendations, which currently diverge widely across Europe, from yearly boosters offered from age 12 in Austria to age 65 and older in Denmark. The authors’ earlier work estimated that, assuming correct COVID-19 death counts, the only Austrian group with a mortality rate implying a number needed to vaccinate below 1,000, residents of nursing homes aged 85 and over, had average life expectancies below one year. With an estimated 2.8 million SARS-CoV-2 infections in Austria in 2024, the reported 1,212 deaths already imply an infection fatality rate of just 0.043 percent, and the weighted analysis suggests even that figure is too high. The study’s most urgent message, however, may be the one about the young: a post-pandemic rise in mortality driven by mental health, external and neurological causes demands confirmation, explanation and intervention, long after the virus itself has faded from the mortality statistics.

Subject of Research: Post-pandemic all-cause mortality patterns and estimation of the residual COVID-19 death burden using weighted multiple-cause-of-death analysis in Austria

Article Title: Post-pandemic mortality patterns and COVID-19 burden considering multiple death causes

Article References: Riedmann, U., Levitt, M., Pilz, S., & Ioannidis, J. P. (2026). Post-pandemic mortality patterns and COVID-19 burden considering multiple death causes. European Journal of Epidemiology. https://doi.org/10.1007/s10654-026-01462-7

Image Credits: AI Generated

DOI: 10.1007/s10654-026-01462-7

Keywords: COVID-19, mortality, Austria, death certificates, multiple causes of death, excess mortality, epidemiology, vaccination policy, life expectancy, infection fatality rate, public health, youth mortality

The study rests on a simple but powerful epidemiological premise: antibodies of the immunoglobulin G class persist for years after infection or vaccination, so their prevalence in a population acts as a cumulative record of exposure. Because hepatitis A and hepatitis E are both transmitted primarily through the faecal-oral route, their seroprevalence patterns are tightly coupled to sanitation, water quality, hygiene practices and socio-economic conditions. When a community improves its water and sanitation infrastructure, the age at which children first encounter these viruses tends to rise, shifting the burden of susceptibility toward older individuals in whom infection is more likely to cause symptomatic disease. This phenomenon, known as epidemiological transition, is one of the central concerns for vaccination policy in low- and middle-income countries undergoing rapid urban development.

To test whether such a transition was underway in Vellore, the team drew on biobanked serum samples from 600 participants in the 2013 survey and 558 participants in the 2022 survey, all aged between one and forty years. Each sample was tested for IgG antibodies specific to hepatitis A virus and hepatitis E virus. The investigators then stratified seroprevalence estimates by age, gender and residential cluster, allowing them to detect not only overall changes between the two survey years but also geographic heterogeneity within the city. Statistical comparisons of seropositivity between years were carried out using proportion tests or Fisher’s exact tests, depending on the structure of the data.

The hepatitis A results were striking in their consistency. Seroprevalence exceeded 80 percent among children aged one to five years in both surveys and climbed to 100 percent among individuals aged sixteen and above, in 2013 as well as 2022. No statistically significant differences in hepatitis A seroprevalence were observed between the two survey years in any age stratum. In practical terms, nearly every resident of urban Vellore had been infected with hepatitis A virus by early adulthood in both eras, and infection continued to occur early in childhood. The virus, in this setting, remains firmly endemic, and the population’s collective immunity remains high.

Hepatitis E told a different story. IgG seroprevalence against this virus was low among children and adolescents in both surveys and increased progressively with age, a pattern consistent with sporadic rather than sustained childhood transmission. Among adults aged twenty-six to forty years, seroprevalence rose from 18 percent in 2013, with a 95 percent confidence interval of 12 to 27 percent, to 24 percent in 2022, with a 95 percent confidence interval of 16 to 32 percent. Although this increase suggests a possible gradual accumulation of exposure in adulthood, the change did not reach statistical significance, and the authors are careful not to overinterpret it. Across both viruses, no significant gender-based differences in seropositivity were detected.

Cluster-wise analysis added a spatial dimension to these findings. Hepatitis A seroprevalence was uniformly high across all residential clusters sampled in Vellore, reflecting the pervasive nature of early-life exposure to the virus throughout the urban environment. Hepatitis E seroprevalence, by contrast, was both low and heterogeneous across clusters, indicating that exposure to this virus is patchy and likely driven by localised factors such as intermittent contamination of water supplies, sanitation gaps in specific neighbourhoods, or differences in food handling practices. This heterogeneity matters for surveillance design, because a citywide average can easily mask pockets of elevated risk where outbreaks of hepatitis E, which can be particularly dangerous for pregnant women, may originate.

Beyond simple prevalence counts, the study employed more sophisticated quantitative tools to probe hepatitis A transmission dynamics. The researchers applied contact matrix and mixture modelling to the serological data to estimate the effective reproduction number, Re, for hepatitis A in each survey year. Mixture modelling, which treats the antibody distribution in a population as a blend of distributions from susceptible and immune individuals, allows researchers to infer the force of infection even from cross-sectional snapshots. The analysis yielded an Re below 1 in both serosurveys, indicating that secondary transmission of hepatitis A was not sustaining epidemic growth in either era, despite the accumulation of susceptible individuals in older age groups over time. This finding suggests that while the age profile of susceptibility may be shifting slowly, the underlying transmission intensity has not yet crossed the threshold that would fuel outbreaks among older, more vulnerable populations.

The implications for vaccination policy are significant. In many middle-income countries that have improved sanitation, hepatitis A has transitioned from a disease of early childhood, where infection is usually asymptomatic, to one affecting older children and adults, in whom clinical illness and occasional severe outcomes are more common. This shift is the classic argument for universal childhood hepatitis A vaccination: immunising children early both protects them and reduces circulation, indirectly shielding older susceptible individuals. The Vellore data show that this transition, while anticipated, has not yet materialised in measurable form; immunity remains high and acquired early, and the effective reproduction number remains below one. The authors note that their findings should inform age-specific considerations for hepatitis A vaccination policy in urban India as it undergoes transition, implying that the window for deciding on vaccination strategy remains open but should be monitored with continued serosurveillance.

For hepatitis E, the picture is one of limited but persistent and age-dependent exposure. The low seroprevalence among the young means that a large fraction of the population reaches adulthood without prior immunity, and the gradual rise in seropositivity with age reflects cumulative adult exposure. The authors highlight the need for targeted hepatitis E surveillance, particularly because the virus causes substantial morbidity in pregnant women and can trigger large outbreaks when water supplies are compromised. The modest, non-significant rise in adult seroprevalence between 2013 and 2022 is consistent with continued low-level transmission that could accelerate under adverse conditions, making sustained monitoring essential.

Perhaps the clearest message of the study is a reaffirmation of the value of water, sanitation and hygiene interventions. The stability of hepatitis A immunity over the decade, and the continued containment of hepatitis E transmission below epidemic thresholds, support continued investment in WASH infrastructure as the backbone of enteric virus control in urban India. At the same time, the study demonstrates the power of repeated, geographically stratified serosurveys using biobanked samples to detect epidemiological change before it becomes clinically visible. As Indian cities continue to grow and modernise, the balance between endemic early-childhood infection and emerging adult susceptibility will determine whether hepatitis A vaccination becomes a public health priority, and whether hepatitis E remains a smouldering, localised threat or flares into wider outbreaks. The Vellore data provide a rigorous baseline against which that future can be measured.

Subject of Research: Decadal changes in IgG seroprevalence of hepatitis A and E virus in urban Vellore, India

Article Title: Decadal changes in IgG seroprevalence of hepatitis A and E virus in Urban Vellore, India: Persistent Endemicity or Epidemiological Shift?

Article References: Madhavan, R., Eswaran, A., Varghese, T., Gandhi, V., Raj, L., Raju, R., Joseph, J. S., Xavier, J. V. L., Rose, W., & John, J. (2026). Decadal changes in IgG seroprevalence of hepatitis A and E virus in Urban Vellore, India: Persistent Endemicity or Epidemiological Shift?. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14413-0

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14413-0

Keywords: Hepatitis A, Hepatitis E, IgG seroprevalence, serosurvey, enteric infections, WASH, epidemiological transition, urban India, effective reproduction number, vaccination policy, Decadal, changes